Session Details

Hot Line: Late Breaking Clinical Trials 4
29 Aug 08:30 - 10:00 Miscellaneous Hot Line Barcelona - Main Auditorium
Chairpersons: Michel KOMAJDA (Paris, France), Hector BUENO (Madrid, Spain)

Abstract Access slides, videos, reports online via ESC Congress 365 Other resources

Presentations list

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30 Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trialMartin LANDRAY (Oxford, United Kingdom)
08:40 Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trialJohn CHAPMAN (Paris, France)
08:45 Panel discussion. 
08:48 Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY studyHiroshi ITOH (Tokyo, Japan)
08:58 Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY studyEva PRESCOTT (Copenhagen, Denmark)
09:03 Panel discussion. 
09:06 Exercise training in diastolic heart failure (Ex-DHF): a multicenter, prospective, randomized, controlled, parallel group trialFrank EDELMANN (Berlin, Germany)
09:16 Discussant review: Exercise training in diastolic heart failure (Ex-DHF): a multicenter, prospective, randomized, controlled, parallel group trial 
09:21 Panel discussion. 
09:24 Catheter Ablation compared with optimized Pharmacological Therapy for Atrial Fibrillation, a randomized multicentre study of quality of life and implantable cardiac monitoring after 12 month follow-upCarina BLOMSTROM-LUNDQVIST (Uppsala, Sweden)
09:34 Discussant review: Catheter Ablation compared with optimized Pharmacological Therapy for Atrial Fibrillation, a randomized multicentre study of quality of life and implantable cardiac monitoring after 12 month follow-upNassir MARROUCHE (Salt Lake City, United States of America)
09:39 Panel discussion. 
09:42 Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation (The REHEARSE-AF study) Julian HALCOX (Swansea, United Kingdom)
09:52 Discussant review: Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation.Christophe LECLERCQ (Rennes, France)
09:57 Panel discussion. 

Who we are

What we do

How we work

More ESC